7B3Y

Structure of a nanoparticle for a COVID-19 vaccine candidate

Summary for 7B3Y

• Entry DOI: 10.2210/pdb7b3y/pdb
• EMDB information: 11997
• Descriptor: Fibronectin binding protein,2-dehydro-3-deoxyphosphogluconate aldolase/4-hydroxy-2-oxoglutarate aldolase (1 entity in total)
• Functional Keywords: sars-cov-2, spytag, vlp, receptor-binding domain, vaccine, covid-19, spycatcher, nanocage, icosahedral, nanoparticle, coronavirus, mi3, virus like particle
• Biological source: Streptococcus pyogenes serotype M49 (strain NZ131); More
• Total number of polymer chains: 1
• Total formula weight: 36000.71

Authors

Duyvesteyn, H.M.E.,Stuart, D.I. (deposition date: 2020-12-01, release date: 2021-01-13, Last modification date: 2024-11-13)

Primary citation

Tan, T.K.,Rijal, P.,Rahikainen, R.,Keeble, A.H.,Schimanski, L.,Hussain, S.,Harvey, R.,Hayes, J.W.P.,Edwards, J.C.,McLean, R.K.,Martini, V.,Pedrera, M.,Thakur, N.,Conceicao, C.,Dietrich, I.,Shelton, H.,Ludi, A.,Wilsden, G.,Browning, C.,Zagrajek, A.K.,Bialy, D.,Bhat, S.,Stevenson-Leggett, P.,Hollinghurst, P.,Tully, M.,Moffat, K.,Chiu, C.,Waters, R.,Gray, A.,Azhar, M.,Mioulet, V.,Newman, J.,Asfor, A.S.,Burman, A.,Crossley, S.,Hammond, J.A.,Tchilian, E.,Charleston, B.,Bailey, D.,Tuthill, T.J.,Graham, S.P.,Duyvesteyn, H.M.E.,Malinauskas, T.,Huo, J.,Tree, J.A.,Buttigieg, K.R.,Owens, R.J.,Carroll, M.W.,Daniels, R.S.,McCauley, J.W.,Stuart, D.I.,Huang, K.A.,Howarth, M.,Townsend, A.R.
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.
Nat Commun, 12:542-542, 2021

PubMed Abstract: There is need for effective and affordable vaccines against SARS-CoV-2 to tackle the ongoing pandemic. In this study, we describe a protein nanoparticle vaccine against SARS-CoV-2. The vaccine is based on the display of coronavirus spike glycoprotein receptor-binding domain (RBD) on a synthetic virus-like particle (VLP) platform, SpyCatcher003-mi3, using SpyTag/SpyCatcher technology. Low doses of RBD-SpyVLP in a prime-boost regimen induce a strong neutralising antibody response in mice and pigs that is superior to convalescent human sera. We evaluate antibody quality using ACE2 blocking and neutralisation of cell infection by pseudovirus or wild-type SARS-CoV-2. Using competition assays with a monoclonal antibody panel, we show that RBD-SpyVLP induces a polyclonal antibody response that recognises key epitopes on the RBD, reducing the likelihood of selecting neutralisation-escape mutants. Moreover, RBD-SpyVLP is thermostable and can be lyophilised without losing immunogenicity, to facilitate global distribution and reduce cold-chain dependence. The data suggests that RBD-SpyVLP provides strong potential to address clinical and logistic challenges of the COVID-19 pandemic.

PubMed: 33483491
DOI: 10.1038/s41467-020-20654-7

Experimental method

ELECTRON MICROSCOPY (3.7 Å)